Soleus Capital Management, L.P. Castle Biosciences Inc Transaction History
Soleus Capital Management, L.P.
- $1.18 Billion
- Q3 2024
A detailed history of Soleus Capital Management, L.P. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 662,332 shares of CSTL stock, worth $18.2 Million. This represents 1.6% of its overall portfolio holdings.
Number of Shares
662,332
Previous 853,628
22.41%
Holding current value
$18.2 Million
Previous $18.6 Million
1.65%
% of portfolio
1.6%
Previous 1.88%
Shares
9 transactions
Others Institutions Holding CSTL
# of Institutions
201Shares Held
24.5MCall Options Held
303KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$83.8 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.83MShares$50.3 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.75MShares$48.1 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$34.7 Million0.61% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.26MShares$34.6 Million2.85% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $724M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...